PCN87 A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
Oct 1, 2009, 00:00
10.1016/S1098-3015(10)74338-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)74338-2/fulltext
Title :
PCN87 A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74338-2&doi=10.1016/S1098-3015(10)74338-2
First page :
Section Title :
Open access? :
No
Section Order :
266